Cellemedy Inc.
- Biotech or pharma, therapeutic R&D
We are developing a next-generation protein drug platform, T-sphaera, based on Apoferritin (the iron-free form of ferritin). On this T-sphaera Platfor, we graft various binding epitopes(Plug) onto multiple surface regions. This modular engineering enables rapid and flexible incorporation of diverse targeting moleties, making T-sphaera a plug-and-play therapeutic platform adaptable to various targets and disease indications. As a result, T-sphaera can function as a targeted anti-cancer therapeutic with antibody-like binding properties, while maintaining the low immunogenicity inherent to human-derived proteins.
- Modular Platform
- Multivalent Binding
- Low Immunogenicity
- High stability
)
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}